all report title image

CRYOABLATION DEVICES MARKET ANALYSIS

Cryoablation Devices Market, By Product Type (Tissue Contact Probe Ablators, Epidermal and Subcutaneous Cryoablation Systems, Tissue Spray Probe Ablators, Others), By Application (Lung Cancer, Liver Cancer, Breast Cancer, Kidney Cancer, Prostate Cancer, Cardiac Arrhythmia), By End User (Hospital & Clinics, Ambulatory Surgical Centre, Research & Manufacturing, Cryotherapy Centers, Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

  • Published In : Jul 2024
  • Code : CMI113
  • Pages :157
  • Formats :
      Excel and PDF
  • Industry : Medical Devices

Cryoablation Devices Market Size and Trends

Global cryoablation devices market is estimated to be valued at USD 408.1 Mn in 2024 and is expected to reach USD 1,021.1 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 14% from 2024 to 2031.

Cryoablation Devices Market Key Factors

Discover market dynamics shaping the industry request sample copy

Rising prevalence of cancer and other cardiovascular diseases, growing geriatric population, and technological advancements in cryoablation devices can drive the market growth. The development of compact, precise, and easy-to-use cryoablation systems have boosted their adoption rate as compared to other conventional ablation procedures. Favorable government policies and rising healthcare expenditures also drives the market growth. However, lack of skilled professionals and limited clinical evidence can hamper the market growth

Growing incidence of cardiac arrhythmias

Global cryoablation devices market growth is driven by rising incidence of cardiac arrhythmias worldwide. Cardiac arrhythmias have become highly common these days due to changing lifestyle and increasing stress levels. Prolonged sitting jobs, lack of physical exercise, diet rich in fat and calories leads to irregular heart rhythms. According to some estimates, over 33 million people suffer from irregular heartbeats globally. Atrial fibrillation is the most frequently diagnosed arrhythmia and associated with several complications if left untreated. Cryoablation is gaining popularity as a treatment option for various types of cardiac arrhythmias due to advantages over other ablation methods. The procedure treats arrhythmia by creating frozen non-conducting scars in the heart muscles to block abnormal conduction pathways. It can isolate and deactivate cardiac tissues responsible for irregular heartbeat. Cryoablation offers higher success rates, minimal effects on heart tissues and reduces risks of complications compared to radiofrequency ablation. Rising healthcare expenditure in developed nations has enabled wider acceptance of advanced ablation devices and techniques for rhythm disorders management. For instance, according to British Heart Foundation in May 2023, the number of people diagnosed with atrial fibrillation, a heart rhythm condition increasing the risk of stroke, has surpassed 1.5 million for the first time, marking a 50% rise since 2013. Approximately 1 in 45 people in the U.K. live with this condition. Atrial fibrillation, the most common type of abnormal heart rhythm, contributes to one in five strokes, making those affected five times more likely to experience a severe stroke. Improved awareness and diagnosis have led to better recognition, yet an estimated 270,000 individuals in the U.K. remain undiagnosed. Symptoms like palpitations, breathlessness, and dizziness are common, though some people may not experience any symptoms, complicating early detection and treatment.

Market Concentration and Competitive Landscape

Cryoablation Devices Market Concentration By Players

Get actionable strategies to beat competition: Get instant access to report

Growing preference for minimally invasive procedures

Growing preference for minimally invasive surgical procedures globally among patients as well as physicians can drive the cryoablation devices market growth. Minimally invasive surgeries are preferred due to benefits such as lesser pain, smaller incisions, shorter hospital stay, quicker recovery time and reduced scarring. Cryoablation, which uses extreme cold to destroy diseased tissue, has emerged as a popular minimally invasive technique for treating cancer and other conditions affecting sites like liver, kidneys and prostate. Cryoablation is often considered as an attractive alternative to traditional surgical procedures for a variety of tumors. Cryoablation of small kidney tumors and early-stage prostate cancer has demonstrated similar clinical outcomes to partial or radical nephrectomy and radical prostatectomy respectively but with considerably lower risks of complications and side effects for patients. As the procedure can be performed via insertion of a probe or catheter through small skin incisions utilizing image guidance, it causes less damage to surrounding healthy tissues as compared to open or laparoscopic surgery. This has led to faster convalescence and return to normal activities for patients. With growing prevalence of cancers worldwide and rising focus on improving quality of life of patients, there has been huge demand for minimally invasive options.

Key Takeaways from Analyst

Global cryoablation devices market growth is driven by factors such as rising geriatric population suffering from cardiac arrhythmias and cancer globally. Furthermore, rising preference for minimally invasive procedures and shorter recovery period associated with cryoablation therapy as compared to traditional surgery can also drive the market growth.

North America currently dominates the market, owing to growing awareness about cryotherapy and established healthcare infrastructure and reimbursement policies in the region. However, Asia Pacific region is expected to offer lucrative opportunities due to growing healthcare expenditure, increasing incidence of cancer, and rapidly expanding medical tourism industry in the region.

Lack of clinical evidence validating cryotherapy for some indications and high costs involved in cryoablation procedures can hamper the market growth. Moreover, limited reimbursement coverage offered for cryoablation therapy in developing regions can also hamper the market growth.

Growing preference for outpatient surgical centers where majority of cryoablation procedures are performed can open new avenues. Ongoing R&D for development of next-generation cryoablation devices with improved features such as integrated imaging, navigation, and robotics can boost adoption of these devices. Market players are also focusing on emerging markets through collaborations to leverage opportunities in these regions.

 Market Challenges: High cost of cryoablation procedures

The high cost of cryoablation procedures can hamper the global cryoablation devices market growth. Cryoablation is a minimally invasive procedure that uses extreme cold produced by liquid nitrogen or argon gas to destroy abnormal or diseased tissue. However, the equipment and devices required for cryoablation are highly sophisticated and expensive. Cryoablation devices use state-of-the-art technologies like imaging systems, probes, consoles and other ancillary parts that increases the cost of treatment. The cost of a basic cryoablation procedure range from USD 10,000 to USD 30,000 depending on the organ being treated and complexity of the case. This does not include additional hospital stay, medication and follow up costs. When compared to alternative treatment options like radiofrequency ablation, microwave ablation or surgery, cryoablation is significantly more expensive. This high cost puts cryoablation out of reach for a large section of patients, especially in developing nations with limited access to healthcare and medical insurance. According to World Bank Data, over 1.2 billion people globally lack access to essential health services and almost 100 million people are pushed into extreme poverty due to out-of-pocket healthcare expenses every year.

Market Opportunities: Increasing adoption of cryotherapy for pain management

Increasing adoption of cryotherapy as a pain management method can provide significant opportunities for growth of global cryoablation devices market. Cryotherapy is gaining recognition from both patients and doctors as a drug-free option for relieving pain. It uses cold temperatures to denervate nerve fibers or cause controlled damage to pain-conducting nerves and tissues. This helps reduce sensitivity and block the transmission of pain signals to the brain. Cryotherapy offers several advantages over drug-based pain therapies and other ablation procedures. It produces precisely targeted pain relief with minimal risks of complications compared to treatments like radiofrequency ablation. Cryoablation procedures are generally non-invasive or minimally invasive, allowing for reduced recovery times. This makes the treatment appealing to a growing population of patients seeking natural or drug-free pain interventions. According to the Centers for Disease Control and Prevention, the use of minimally invasive procedures for chronic pain management had increased by 50% between 2000 to 2010 in the U.S.

Cryoablation Devices Market By Product Type

Discover high revenue pocket segments and roadmap to it: Get instant access to report

By Product Type - Success through Precision and Effectiveness

In terms of product type, tissue contact probe ablators segment is estimated to contribute the highest market share of 30.2% in 2024, due to its precise tissue contact and ablation. Tissue contacts probe ablators work by direct contact of probes with target tissues, allowing for precise placement and localized energy delivery. This ensures effective treatment by annihilating diseased tissues with minimal damage to surrounding healthy tissues. The precise contact and focused energy deposition aid in treatment of difficult to reach tumor sites like those in lungs, liver, and others without requiring surgery. Being minimally invasive, these cause lesser pain and trauma to patients as compared to surgical procedures. The reproducible, localized treatment action and swift recovery help address patient expectation of effective yet less painful treatment options. Continuous product innovation enables treatment of complex tumor configurations with multiple probes in single sitting, improving clinical outcomes. Strong clinical evidence validating safety, efficacy and procedural benefits drives continued patient and physician preference for tissue contact probe ablators over other cryoablation product alternatives.

By Application - Optimizing Clinical Outcomes

In terms of application, lung cancer segment is estimated to contribute the highest market share of 25.1% in 2024, due to enhanced clinical viability of cryoablation in lung malignancies. Cryoablation offers distinct advantages over surgical resection for lung tumors, given anatomical location of lungs and sensitivity of pulmonary system. Minimally invasive cryoablation aids in treatment of early as well as late-stage lung tumors across central, peripheral and subpleural locations with minimal loss of lung functioning. This is vital as lung function significantly impacts clinical outcomes and quality of life post-treatment. Ongoing improvements in cryoablation technologies enable treating previously inoperable tumors, thus, boosting adoption. Cryoablation also allows repeated sessions if required without added risk, thus, optimizing clinical management of lung cancer. The ability to deploy multiple probes per sitting helps more complete ablations even in complex lung tumor configurations. This enhances local tumor control rates and improves survival benefits comparable to other standard therapies. Supported by robust clinical research substantiating outcomes, cryoablation is now considered as mainstay treatment option in lung malignancies.

By End User - A Culture of Care

In terms of end user, hospitals & clinics segment is estimated to contribute the highest market share of, due to their focus on furthering standards of cancer care. Hospitals & clinics consider cryoablation as an important addition to care pathways due to minimally invasive profile, favorable safety over surgery and ability to optimize multidisciplinary management of cancer patients. A significant number of hospitals worldwide have established dedicated cryoablation suites as cryoablation gains traction as a mainstream treatment offering. Their continued investments in procuring latest ablation technologies, training medical personnel and partnering with key opinion leaders reinforce their commitment towards furthering cancer treatment standards. Cryoablation also aligns well with hospitals' focus on timely and effective care, lower readmission rates and improving overall patient experience. Strategic partnerships with community oncology centers can expand access to cryoablation therapies. A culture of providing world-class cancer care, enriching clinical expertise and ensuring best outcomes and experiences for patients drives a sizable portion of cryoablation procedures to be performed in hospitals versus other end users.

Regional Insights

Cryoablation Devices Market Regional Insights

To learn more about this report, request sample copy

North America dominates the global cryoablation devices market with an estimated market share of 40.2% in 2024. The region accounts for the largest market share, owing to the highly developed healthcare infrastructure and higher adoption of technologically advanced cryoablation devices. The presence of leading cryoablation device manufacturers in the U.S. also drives the market growth. Moreover, favorable reimbursement policies and increasing demand for minimally invasive procedures for treating cancer and cardiac arrhythmias have boosted demand.

Asia Pacific region is the fastest growing market for cryoablation devices globally. Factors such as large population base suffering from cancer and increasing focus on developing a robust healthcare system can drive the market growth. Rising medical tourism owing to availability of low-cost treatments and devices can boost demand from international patients. Several new local manufacturers are entering the market by offering devices at competitive prices. This has increased the affordability and accessibility of cryoablation technologies.

Market Report Scope

Cryoablation Devices Market Report Coverage

Report Coverage Details
Base Year: 2023 Market Size in 2024: US$ 408.1 Mn
Historical Data for: 2019 to 2023 Forecast Period: 2024 to 2031
Forecast Period 2024 to 2031 CAGR: 14% 2031 Value Projection: US$ 1,021.1 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: South Africa, North Africa, Central Africa
Segments covered:
  • By Product Type: Tissue Contact Probe Ablators, Epidermal and Subcutaneous Cryoablation Systems, Tissue Spray Probe Ablators, Others
  • By Application: Lung Cancer, Liver Cancer, Breast Cancer, Kidney Cancer, Prostate Cancer, Cardiac Arrhythmia
  • By End User: Hospital & Clinics, Ambulatory Surgical Centre, Research & Manufacturing, Cryotherapy Centers, Others 
Companies covered:

Boston Scientific Corporation, Micro Port Scientific Corporation., Medtronic, COOPERSURGICAL, INC., ATRICURE, INC., BVM Medical Limited, CPSI Biotech, Ice Cure Medical, METRUM CRYOFLEX Sp. z o.o., AtriCure, Inc., HealthTronics, Inc., IceCure Medical Ltd., Sanarus Technologies, Inc., Stryker Corporation, CryoLife, Inc., CMS Medical, Erbe Elektromedizin GmbH

Growth Drivers:
  • Growing Incidence of Cardiac Arrhythmias
  • Growing preference for minimally invasive procedures
Restraints & Challenges:
  • High cost of cryoablation procedures
  • Lack of skilled professionals

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Cryoablation Devices Industry News

  • In April 2024, AtriCure, Inc. a pioneer in surgical treatments for atrial fibrillation (Afib) and related conditions, has introduced the cryoSPHERE+ cryoablation probe. This new device utilizes advanced insulation technology to reduce freeze times by 25% compared to AtriCure’s previous cryoSPHERE device. Currently, the product is in an extended limited launch phase in the United States, with a full launch anticipated by the end of the second quarter.
  • In August 2023, Boston Scientific Corporation, biomedical/biotechnology engineering firm and multinational manufacturer of medical devices has received FDA approval for its POLARx Cryoablation System, designed for treating patients with paroxysmal atrial fibrillation (AF). This new system includes the POLARx FIT Cryoablation Balloon Catheter, which uniquely offers two balloon sizes (28mm and 31mm) within a single catheter.
  • In June 2021, Medtronic plc a leader in medical technology, has received expanded FDA approval for its Arctic Front Family of Cardiac Cryoablation Catheters. The approval allows for the treatment of recurrent symptomatic paroxysmal atrial fibrillation as an initial rhythm control strategy, offering an alternative to antiarrhythmic drug therapy.
  • In September 2023, IceCure Medical Ltd. has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA) for its ProSense System as a Class III medical device. This system utilizes minimally-invasive cryoablation technology to freeze and destroy tumors, offering an alternative to surgical removal. Previously registered as Class II devices, the ProSense System's disposable cryoprobes and introducers were also included in this updated approval.

*Definition: Global Cryoablation Devices Market involves medical devices and technologies that use extreme cold temperatures to eliminate diseased tissue through a minimally-invasive surgical procedure known as cryoablation or cryotherapy. Cryoablation devices feature advanced cryogenic technology to precisely deliver controlled freezing to aberrant anatomical sites, thereby destroying unhealthy or dysfunctional cells, reducing symptoms, and minimizing patient recovery time compared to traditional open surgeries. The cryoablation market includes different types of probes, needles, catheter systems and other tools that enable cryosurgical ablation of unfavorable tissues in the treatment of cancers, arrhythmias, and other conditions.

Market Segmentation

  • Product Type Insights (Revenue, USD Mn, 2019 - 2031)
    • Tissue Contact Probe Ablators
    • Epidermal and Subcutaneous Cryoablation Systems
    • Tissue Spray Probe Ablators
    • Others
  •  Application Insights (Revenue, USD Mn, 2019 - 2031)
    • Lung Cancer
    • Liver Cancer
    • Breast Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Cardiac Arrhythmia
  •  End User Insights (Revenue, USD Mn, 2019 - 2031)
    • Hospital & Clinics
    • Ambulatory Surgical Centre
    • Research & Manufacturing
    • Cryotherapy Centers
    • Others
  • Regional Insights (Revenue, USD Mn, 2019 - 2031)
    • North America
      • U.S.
      • Canada
    • Latin America
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
    • Europe
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN               
      • Rest of Asia Pacific
    • Middle East
      • GCC Countries
      • Israel
      • Rest of Middle East
    • Africa
      • South Africa
      • North Africa
      • Central Africa
  • Key Players Insights
    • Boston Scientific Corporation
    • Micro Port Scientific Corporation.
    • Medtronic
    • COOPERSURGICAL, INC.
    • ATRICURE, INC.
    • BVM Medical Limited
    • CPSI Biotech
    • Ice Cure Medical
    • METRUM CRYOFLEX Sp. z o.o.
    • AtriCure, Inc.
    • HealthTronics, Inc.
    • IceCure Medical Ltd.
    • Sanarus Technologies, Inc.
    • Stryker Corporation
    • CryoLife, Inc.
    • CMS Medical
    • Erbe Elektromedizin GmbH

Share

About Author

Komal Dighe is a Management Consultant with over 8 years of experience in market research and consulting. She excels in managing and delivering high-quality insights and solutions in Health-tech Consulting reports. Her expertise encompasses conducting both primary and secondary research, effectively addressing client requirements, and excelling in market estimation and forecast. Her comprehensive approach ensures that clients receive thorough and accurate analyses, enabling them to make informed decisions and capitalize on market opportunities.

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global Cryoablation Devices Market size is estimated to be valued at USD 408.1 million in 2024 and is expected to reach USD 1,021.1 million in 2031.

The CAGR of global cryoablation devices market is projected to be 14% from 2024 to 2031.

Growing incidence of cardiac arrhythmias and growing preference for minimally invasive procedures are the major factors driving the growth of global cryoablation devices market.

High cost of cryoablation procedures and lack of skilled professionals are the major factors hampering the growth of global cryoablation devices market.

In terms of product type, tissue contact probe ablators segment is estimated to dominate the market in 2024.

Boston Scientific Corporation, Micro Port Scientific Corporation., Medtronic, COOPERSURGICAL, INC., ATRICURE, INC., BVM Medical Limited, CPSI Biotech, Ice Cure Medical, METRUM CRYOFLEX Sp. z o.o., AtriCure, Inc., HealthTronics, Inc., IceCure Medical Ltd., Sanarus Technologies, Inc., Stryker Corporation, CryoLife, Inc., CMS Medical, Erbe Elektromedizin GmbH are the major players.

North America is expected to lead the global cryoablation devices market.
Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Select a License Type





Logo

Credibility and Certifications

ESOMAR
DUNS Registered

860519526

Clutch
Credibility and Certification
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.